Patients with a very rare immune disorder who have gotten the gene therapy have experienced sustained long-term immune ...
Enhertu Benefit in HER2-Low Breast Cancer That's Also HR-Negative Supported by Longer Follow-Up Data
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.
The funding includes an initial tranche of $7.5 million in equity and technical support, and the biotech and the foundation will form a joint steering committee.
In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...
NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback